- Home
- ALTS vs IKNA Comparison
ALTS vs IKNA Comparison
Compare ALTS & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- IKNA
- Stock Information
- Founded
- ALTS 1976
- IKNA 2016
- Country
- ALTS United States
- IKNA United States
- Employees
- ALTS N/A
- IKNA N/A
- Industry
- ALTS
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- IKNA Health Care
- Exchange
- ALTS NYSE
- IKNA Nasdaq
- Market Cap
- ALTS 84.1M
- IKNA 81.6M
- IPO Year
- ALTS N/A
- IKNA 2021
- Fundamental
- Price
- ALTS $5.93
- IKNA $1.45
- Analyst Decision
- ALTS
- IKNA Buy
- Analyst Count
- ALTS 0
- IKNA 2
- Target Price
- ALTS N/A
- IKNA $3.00
- AVG Volume (30 Days)
- ALTS 231.2K
- IKNA 175.4K
- Earning Date
- ALTS 11-12-2024
- IKNA 03-11-2025
- Dividend Yield
- ALTS N/A
- IKNA N/A
- EPS Growth
- ALTS N/A
- IKNA N/A
- EPS
- ALTS N/A
- IKNA N/A
- Revenue
- ALTS $7,110,000.00
- IKNA $659,000.00
- Revenue This Year
- ALTS N/A
- IKNA N/A
- Revenue Next Year
- ALTS N/A
- IKNA N/A
- P/E Ratio
- ALTS N/A
- IKNA N/A
- Revenue Growth
- ALTS N/A
- IKNA N/A
- 52 Week Low
- ALTS $0.58
- IKNA $1.22
- 52 Week High
- ALTS $7.09
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- ALTS 56.75
- IKNA 40.55
- Support Level
- ALTS $5.84
- IKNA $1.39
- Resistance Level
- ALTS $6.64
- IKNA $1.53
- Average True Range (ATR)
- ALTS 0.65
- IKNA 0.06
- MACD
- ALTS -0.01
- IKNA -0.00
- Stochastic Oscillator
- ALTS 71.10
- IKNA 37.50
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.